Product Specifications:
Contents: Retatrutide
Size: 20mg
Form: Lyophilized powder
Purity: >99%

Product Overview
Mechanism of Action & Triple-Agonist Design

GLP-1 Receptor Activation: Retatrutide acts as an agonist at the glucagon-like peptide-1 (GLP-1) receptor, slowing gastric emptying and acting on

central nervous system pathways to suppress appetite and increase satiety.
GIP Receptor Activation: Concurrent glucose-dependent insulinotropic polypeptide (GIP) receptor activity enhances nutrient-stimulated insulin secretion while modulating adipose tissue metabolism and potentially mitigating GLP-1-induced gastrointestinal side effects.
Glucagon Receptor Activation: Unlike single or dual agonists (e.g., semaglutide or tirzepatide), retatrutide targets the glucagon receptor (GCGR). This increases energy expenditure, promotes lipid mobilization, and reduces intrahepatic fat accumulation.

Clinical Efficacy (Phase 2 & Phase 3 Data)

Weight Reduction: In a 48-week Phase 2 randomized controlled trial published in The New England Journal of Medicine, participants

receiving the highest dose (12 mg weekly) achieved a mean body weight reduction of 24.2%.
Phase 3 Outcomes: Across completed Phase 3 trials (the TRIUMPH clinical program), mean weight loss reached 28.3% at 80 weeks in adults with general obesity (TRIUMPH-1) and up to 28.7% at 68 weeks in adults with knee osteoarthritis (TRIUMPH-4).
Glycemic Control: Studies in populations with type 2 diabetes (TRIUMPH-2, TRANSCEND-T2D-1) demonstrated mean HbA1c reductions between -1.4% and -2.0% alongside significant weight reduction.
Cardiometabolic & Hepatic Biomarkers: Trial data indicate secondary improvements in metabolic parameters, including reductions in systolic blood pressure, serum triglycerides, high-sensitivity C-reactive protein (hsCRP), and liver fat content.

Safety, Adverse Effects, and Tolerability

Gastrointestinal Effects: The most common adverse events mirror those of the incretin class, primarily consisting of dose-dependent nausea, diarrhea, vomiting, and constipation, which occur mostly during initial dose titration.
Cardiovascular Parameters: Mild, transient increases in resting heart rate have been observed, consistent with glucagon and GLP-1 receptor activation profiles.
Regulatory & Research Status: Retatrutide (LY3437943) remains an investigational agent in clinical trials and has not received approval from regulatory bodies (such as the FDA, EMA, or MHRA) for human clinical administration outside of authorized clinical research.
This product is provided strictly for laboratory research and analytical testing by qualified

scientific professionals. It is not approved for human or veterinary administration, diagnostic protocols, or therapeutic applications.